Printer Friendly

SUPRA MEDICAL REVEALS NEW ULTRASOUND SCANNER

 LONDON, Feb. 1 /PRNewswire/ -- Supra Medical Corp. (NASDAQ: SUM.EC) today revealed the development of a new ultrasound model, the EDC III, which is a superior, more mobile yet significantly less costly instrument than the company's Supra Scanner(R).
 Like its predecessor, the new version is dedicated to the non- invasive diagnosis and monitoring of skin disorders, but it will have the capability of addressing other medical conditions as well.
 Final production engineering has been authorized, and the new model is expected to become commercially available by early April. "We've acted on the recommendations of the medical professionals who have been field testing the scanner," said Evelyna Dyson Cantwell, the company's president. "We expect that the features incorporated into the latest version will facilitate considerably its entrance into the huge skin disorder diagnostic market."
 During the past several months, the company's associates at the Tissue Repair Research Unit of London University's United Medical and Dental Schools (of Guy's and St. Thomas's hospitals) have been raising the informational content of the scanner's output. Dr. Mary Dyson, who leads this group, observed, "Our original objective was to improve operational ease by converting the scanner's inherent capabilities into an expert system. We have not only achieved that goal but we've surpassed it."
 Supra Medical's chairman and chief executive officer, Jack Cantwell, commented, "Improving cost-effectiveness is a high priority mission at our company. We take especial satisfaction in delivering on this promise with our new scanner. Present indications are that the list price of the EDC III will represent a 30 percent discount from the Supra Scanner(R) list price."
 Supra Medical Corp. develops and markets proprietary medical products which are used in the diagnosis, monitoring and ongoing treatment of skin disorders such as wounds, ulcerations, burns and other skin disorders including skin cancers and melanomas.
 /delval/
 -0- 2/1/93
 /CONTACT: George Stasen, COO/EVP of Supra Medical Corp., 800-388-6769/
 (SUM.EC)


CO: Supra Medical Corp. ST: Pennsylvania IN: HEA SU: PDT

MJ-CC -- PH036 -- 6641 02/01/93 16:08 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:338
Previous Article:Bear Stearns Mtge. Securities 1993-1 Rated 'AAA/AA' By Fitch -- FITCH FINANCIAL WIRE --
Next Article:EVEREX BEGINS DOWNSIZING COMPANY BY SELLING NON-CORE BUSINESSES; SALE OF MASS STORAGE & ESIX SOFTWARE DIVISIONS PENDING FINAL COURT APPROVAL
Topics:


Related Articles
TOPOX: AGREEMENT SIGNED TO MANUFACTURE INNOVATIVE MEDICAL DEVICES
NASA PROJECT TO FURTHER ULTRASOUND DIAGNOSTIC FRONTIERS
SUPRA MEDICAL EXPANDS NON-INVASIVE BREAST DISEASE DIAGNOSTIC PROGRAM
PORTABLE VERSION OF SUPRA SCANNER(R) SLASHES COSTS AND BROADENS MARKET
SUPRA MEDICAL RELEASES SECOND QUARTER RESULTS
/C O R R E C T I O N -- SUPRA MEDICAL/
SUPRA MEDICAL CORP. RESTRUCTURES AND ADDS MANAGEMENT PERSONNEL
SUPRA MEDICAL CORP. RELEASES THIRD QUARTER RESULTS
SUPRA MEDICAL CORP. AND SONIX, INC. ANNOUNCE ULTRASOUND COLLABORATIVE EFFORT
SUPRA MEDICAL REALIGNS MANAGEMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters